PATH | VRL
Menu

Persistence of Immune Responses to the HPV-16/18 AS04-Adjuvanted Vaccine in Women Aged 15-55 Years and First-Time Modelling of Antibody Responses in Mature Women: Results From an Open-Label 6-Year Follow-Up Study

This article, published in BJOG: An International Journal of Obstetrics & Gynaecology, reports on a study to evaluate the HPV-16/18 AS04-adjuvanted vaccine's long-time immunogenicity persistence in women. The authors found that six years after vaccination, immune responses induced by the vaccine were sustained in all age groups.

Author: Schwarz T, Spaczynski M, Kaufmann A, et al.

Published: 2015

» Visit web page (English)

(Located at onlinelibrary.wiley.com)

Citation: Schwarz T, Spaczynski M, Kaufmann A, et al. Persistence of Immune Responses to the HPV-16/18 AS04-Adjuvanted Vaccine in Women Aged 15-55 Years and First-Time Modelling of Antibody Responses in Mature Women: Results From an Open-Label 6-Year Follow-Up Study. BJOG: An International Journal of Obstetrics & Gynaecology. 2015;122(1):107-118.

Resource types: Peer-reviewed journal

Diseases/vaccines: Human papillomavirus (HPV)

Topics: Vaccine safety and performance, Disease/vaccine specific information

Regions: North America and Europe